

DAFTAR PUSTAKA

- ADA (American Diabetes Assosiation), 2013. Clinical Practice Recommendations Report of the Expert Commite on the Diagnosis and Classifications of Diabetes Mellitus Diabetes Care, USA: p.S4-S24.
- Afif, H., 2015. Hubungan Pemberian Antibiotik Berdasarkan Hasil Uji Sensitivitas Terhadap Pencapaian ClinicalOutcome Pasien dengan Ulkus Diabetik di Rumah Sakit Umum Pusat Haji Adam Malik Medan. Medan: Universitas Sumatera Utara.
- Ajie, R.B., 2015. WHITE DRAGON FRUIT (*Hylocereus undatus*) POTENTIAL AS DIABETES MELLITUS TREATMENT. , 4, pp.69–72.
- Akbarzadeh, A. *et al.* (2007) “INDUCTION OF DIABETES BY STREPTOZOTOCIN IN RATS,” 22(2), pp. 60–64.
- Al-Ishaq, R. K. *et al.* (2019) “Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels,” *Biomolecules*, 9(9). doi: 10.3390/biom9090430.
- Alkhalidy, H., Wang, Y. and Liu, D. (2018) “Dietary flavonoids in the prevention of T2D: An overview,” *Nutrients*, 10(4), pp. 1–33. doi: 10.3390/nu10040438.
- Anuj Y, Rewa K, Ashwani Y, J.P. M, Seweta S, Shashi P. Antioxidants and its functions in human body. *Res Environ Life Sci.* 2016;9(11):1328–31
- Aulia Nur R, et all. (2018). *Intracellular antioxidant activity of Muntingia calabura leaves methanolic extract.* 10(3), 210–214. <https://doi.org/10.13057/nusbiosci/n100402>
- Aronson, D. 2008. Hyperglycemia and the pathobiology ofdiabetic complications. *Adv. Cardiol.* 45: 1-16.
- Bajaj S. and Khan A. Antioxidant and diabetes. *Indian Journal of Endocrinology and Metabolism.* 2012;16(2): 267-271a

- Binawati, D. K., dan Amilah, S. 2013. Effect of Cherry Leaf (*Muntingia calabura* L.) Bioinsecticides Extract Towards Mortality of Worm Soil (*Agrotis ipsilon*) and Armyworm (*Spodoptera exiqua*) on Plant Leek (*Allium fistolum*). *Wahana*, 61(2):51-57.
- Bosch R, Philips N, Suarez-Perez JA, Juarranz A, Devmurari A, Chalensouk-Khaosaat J, Gonzalez S. 2015. Mechanisms of photoaging and cutaneous photocarcinogenesis, and photoprotective strategies with phytochemicals. *Antioxidants* 4: 248-268.
- Buettner, R., Schölmerich, J. and Bollheimer, L. C. (2007) "High-fat diets: Modeling the metabolic disorders of human obesity in rodents," *Obesity*, 15(4), pp. 798–808. doi: 10.1038/oby.2007.608.
- Ceretta, L. B., Réus, G. Z., Abelaira, H. M., Ribeiro, K. F., Zappellini, G., Felisbino, F. F., Steckert, A. V., Dal-Pizzol, F., & Quevedo, J. (2012). Increased oxidative stress and imbalance in antioxidant enzymes in the brains of alloxan-induced diabetic rats. *Experimental Diabetes Research*, 2012. <https://doi.org/10.1155/2012/302682>
- Clement S, Braithwaite SS, Magee MF, et al. *Management of diabetes and hyperglycemia in hospitals*. *Diabetes Care* 2004; 27:553-91.
- Dungan KM, Braithwaite SS, Preiser JC. *Stress hyperglycaemia*. *Lancet* 2009; 373:1798-807.
- Egi M, Bellomo R, Stachowski E, et al. *Blood glucose concentration and outcome of critical illness: the impact of diabetes*. *Crit Care Med* 2008;36:2249-55.
- Eizirik, D. L., Pasquali, L. and Cnop, M. (2020) "Pancreatic β -cells in type 1 and type 2 diabetes mellitus: different pathways to failure," *Nature Reviews Endocrinology*, 16(7), pp. 349–362. doi: 10.1038/s41574-020-0355-7.
- Farzaei, M. H. et al. (2019) *Targeting inflammation by flavonoids: Novel therapeutic strategy for metabolic disorders*, *International Journal of Molecular Sciences*. doi: 10.3390/ijms20194957.

- Fiana, N., & Oktaria, D. (2016). Pengaruh Kandungan Saponin dalam Daging Buah Mahkota Dewa (*Phaleria macrocarpa*) terhadap Penurunan Kadar Glukosa Darah. *Majority*, 5(4), 128–132.
- Haerani, A., Chaerunisa, A. Y. and Subarnas, A. (2019) “Antioxidant Activities of *Muntingia calabura*, *Syzygium cumini*, *Ocimum basilicum*, and *Eleutherine bulbosa* using DPPH Method,” *Indonesian Journal of Pharmaceutics*, 1(2). doi: 10.24198/idjp.v1i2.21531.
- Hagerman AE, Robbins CT, Weerasuriya Y, Wilson Tc, Mc Arthur C. 1992. Tannin chemistry in relation to digestion. *Journal of Range Management* 45:57-62.
- Harborne JB. 1987. *Metode Fitokimia; Penuntun Cara Modern Menganalisis Tumbuhan*. Terbitan ke-2. Padmawinata K, Soediro I, penerjemah; Bandung: ITB. Hlm 102-104. Terjemahan dari: *Phytochemical Methods of agauding the Modern way of Analyzing Plant*.
- Huang, H., Ullah, F., Zhou, D. X., Yi, M., & Zhao, Y. (2019). Mechanisms of ROS regulation of plant development and stress responses. *Frontiers in Plant Science*, 10(June), 1–10. <https://doi.org/10.3389/fpls.2019.00800>
- Hudish LI, Reusch JEB, Sussel L. b b Cell dysfunction during progression of metabolic syndrome to type 2 diabetes REVIEW SERIES: MECHANISMS UNDERLYING THE METABOLIC SYNDROME. *J Clin Invest*. 2019;129(10):4001.
- IDF Diabetes Atlas 9th Edition, 2019.
- Ighodaro, O. M., Adeosun, A. M. and Akinloye, O. A. (2017) “Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies,” *Medicina (Lithuania)*, 53(6), pp. 365–374. doi: 10.1016/j.medici.2018.02.001.
- Kementerian Kesehatan RI. 2014. *Situasi dan Analisis Diabetes*. Jakarta: Kementerian Kesehatan RI.

- Kementrian Kesehatan Republik Indonesia (2018) *Hasil Utama Riskesdas 2018*. Jakarta.
- Kwon, S., Kim, Y. J., & Kim, M. K. (2008). Effect of fructose or sucrose feeding with different levels on oral glucose tolerance test in normal and type 2 diabetic rats. *Nutrition Research and Practice*, 2(4), 252. <https://doi.org/10.4162/nrp.2008.2.4.252>
- Liu, Y. J. *et al.* (2014) "Dietary flavonoids intake and risk of type 2 diabetes: A meta-analysis of prospective cohort studies," *Clinical Nutrition*, 33(1), pp. 59–63. doi: 10.1016/j.clnu.2013.03.011.
- Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, *et al.* *Harrison's principles of internal medicine*, 18th ed. : McGraw-Hill; 2012.
- Mahmood, N. D. *et al.* (2014) "Muntingia calabura: A review of its traditional uses, chemical properties, and pharmacological observations," *Pharmaceutical Biology*, 52(12), pp. 1598–1623. doi: 10.3109/13880209.2014.908397.
- Malaisse, W. J., Malaisse-Lagae, F., Sener, A. & Pipeleers, D. G. 1982. Determinants of the selective toxicity of alloxan to pancreatic B cell. *Proc. Natl. Acad. Sci. USA*, 79, 927-930
- Malviya, N., Jain, S., & Malviya, S., 2010, Review Antidiabetic Potential of Medicinal Plants, *Acta Poloniae Pharmaceutica-Drug Research*, 67(2), 113-118.
- Mandal, M., Varghese, A., Gaviraju, V. K., Talwar, S. N., & Malini, S. S. (2019). Impact of hyperglycaemia on molecular markers of oxidative stress and antioxidants in type 2 diabetes mellitus. *Clinical Diabetology*, 8(4), 215–222. <https://doi.org/10.5603/DK.2019.0015>
- Marciniak A, Brzeszczyńska, J., Gwoździński, K., Jegier, A., 2009. Antioxidant Capacity and Physical Exercise. *Biology of Sport*. 26 (3):197-213.
- Mittler R. ROS Are Good. *Trends Plant Sci*. 2017;22(1):11–9.
- Modlinska, K. and Pisula, W. (2020) "The Norway rat, from an obnoxious pest to a laboratory pet," *eLife*. Edited by S. R. F. King *et al.* *eLife*

- Sciences Publications, Ltd, 9, p. e50651. doi: 10.7554/eLife.50651.
- Nawaekasari M, 2012. Efek senyawa polifenol ekstrak biji kakao (theobroma cacao l) terhadap pertumbuhan bakteri lactobacillus acidophilus. Skripsi. Fakultas Kedokteran Gigi Universitas Jember.
- Newsholme, P. *et al.* (2014) "Nutrient regulation of insulin secretion and action," *Journal of Endocrinology*, 221(3). doi: 10.1530/JOE-13-0616.
- Nirmala, M., Priya, R., Shankar, T., & Malarvizhi, A. (2020). *MEDICINAL VALUES OF Muntingia calabura LEAVES*. June.
- Nirwana A.P., Astirin O.P. and Widiyani T., 2015, Skrining Fitokimia Ekstrak Etanol Daun Benalu Kersen (*Dendroptoe pentandra* L. Miq.), *EL-VIVO*, 3(2), 9–15.
- Nosiri C.I., *et al.* (2016). Histopatology of the Pancreatic Cells of Alloxan Induced Wistar Rats Treated with Psidium Guajava Ethanolic Leaf Extract. *Journal of Biotechnology of Biochemistry*, 28-32.
- Ojiako, O. A., Chikezie, P. C. and Ogbuji, A. C. (2016) "Blood glucose level and lipid profile of alloxan-induced hyperglycemic rats treated with single and combinatorial herbal formulations," *Journal of Traditional and Complementary Medicine*, 6(2), pp. 184–192. doi: 10.1016/j.jtcme.2014.12.005.
- Panagiotakos, D. B. *et al.* (2009) "Long-term tea intake is associated with reduced prevalence of (type 2) diabetes mellitus among elderly people from Mediterranean Islands: MEDIS epidemiological study," *Yonsei Medical Journal*, 50(1), pp. 31–38. doi: 10.3349/ymj.2009.50.1.31.
- Panche, A. N., Diwan, A. D. and Chandra, S. R. (2016) 'Flavonoids: An overview', *Journal of Nutritional Science*, 5, pp. 1–15. doi: 10.1017/jns.2016.41.
- Perkeni. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia Tahun 2011-2015.
- Peluso, I., Raguzzini, A. and Serafini, M. (2013) "Effect of flavonoids on circulating levels of TNF- α and IL-6 in humans: A systematic review

- and meta-analysis,” *Molecular Nutrition and Food Research*, 57(5), pp. 784–801. doi: 10.1002/mnfr.201200721.
- Radenković, M., Stojanović, M. and Prostran, M. (2016) “Experimental diabetes induced by alloxan and streptozotocin: The current state of the art,” *Journal of Pharmacological and Toxicological Methods*. Elsevier B.V., 78, pp. 13–31. doi: 10.1016/j.vascn.2015.11.004.
- Rahman S, Wati A, Asariningtyas EM. 2017. Efek Antiinflamasi Ekstrak Etanol Daun Kersen (*Muntingia Calabura L.*) Pada Mencit (*Mus Musculus*). *As-Syifaa* 9 (1): 51-57.
- Robinson T. 1995. *Kandungan Organik Tumbuhan Tinggi*. Padmawinata K, penerjemah: Bandung: ITB hlm 191-192. Terjemahan dari: *Organic Contents of Higher Plants*.
- Robertson, R.P., J. Harmon, P.O. Tran, Y. Tanaka and H.Takahashi. 2003. Glucose toxicity in beta-cells: type 2diabetes, good radicals gone bad, and the glutathioneconnection. *Diabetes* 52: 581-587.
- Sari, C. I. P. 2012. Kualitas minuman serbuk Kersen (*Muntingia calabura L.*) dengan variasi konsentrasi maltodekstrin dan ekstrak kayu secang (*Caesalpinia sappan L.*). Skripsi, Fakultas Teknobiologi, Universitas Atma Jaya, Yogyakarta.
- Schieber M, Chandel NS. ROS function in redox signaling. *Curr Biol*. 2014;24(10):453–62.
- Shidar M, K Yhirupathi, G Chaitanya, B Ravi Kumar, G Krishna Mohan. 2011. Antidiabetic effect of leaves of *Muntingia calabura L* in normal and alloxan induced diabetic rats. *Pharmacologyonline* 2:626-632.
- Sindhe V, Gupta V, Sharma K, Bhatnagar S, Kumari R, Dhaka N. Potential applications of antioxidants – A review. *J Pharm Res [Internet]*. 2013;7(9):828–35. Available from: <http://dx.doi.org/10.1016/j.jopr.2013.10.001>
- Simon, K. and Wittmann, I. (2019) “Can blood glucose value really be

- referred to as a metabolic parameter?," *Reviews in Endocrine and Metabolic Disorders*, 20(2), pp. 151–160. doi: 10.1007/s11154-019-09504-0.
- Situmorang, N., Utara, U. S. and Utara, S. (2020) 'Malondialdehyde', *Definitions*, 2(2). doi: 10.32388/dxq704
- Sugiono. 2014. *Metode Penelitian Kombinasi*. Bandung : Alfabeta.
- Sunita, R., Sahidan Sahidan, & Hidayat, R. (2020). Evaluation of Malondialdehyde in Type 2 Diabetes Mellitus Patients as Oxidative Stress Markers in Bengkulu Population. *Bioscientia Medicina: Journal of Biomedicine and Translational Research*, 4(3), 45–54. <https://doi.org/10.32539/bsm.v4i3.146>
- Suyono S. Diabetes Melitus di Indonesia. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, penyunting. Buku Ajar Ilmu Penyakit Dalam. Edisi ke-5. Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. 2009:1877-9.
- Susanto T. 2013. *Diabetes, Deteksi, Pencegahan, Pengobatan*. Jakarta: Buku Pintar. Hlm. 95-112.
- Szkudelski, T. 2001. The mechanism of alloxan and streptozotocin action in cells of the rat pancreas. *Physiol. Res.* 50: 536-546.
- Taslim, N. A., Asfar, M., Yuliana, I., Lestari, D., & Waris, R. (2021). Effect of drying method treatment on total phenolic, flavonoids and antioxidant activity of Kersen (*Muntingia calabura* L.) leaves. *Annals of the Romanian Society for Cell Biology*, 25(4), 7822–7830.
- Tiwari, A.K., J.M. Rao. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospect. *Current Science*, 2002; vol 83, 1 (30-38).
- Tokarz, V. L., MacDonald, P. E. and Klip, A. (2018) "The cell biology of systemic insulin function," *Journal of Cell Biology*, 217(7), pp. 1–17. doi: 10.1083/jcb.201802095.

- Upendra R M, Sreenivasulu M, Chengaiah B, Jaganmohan R K, Madhusudhana C C. 2010. Herbal medicines for diabetes mellitus: A review. *Int J PharmTech Res.* 2(3):1883–1892.
- Valko, M., Leibfritz, D., Moncola, J., Cronin, M.T.D., Mazur, M., Telser, J., 2007, Review: Free radicals and antioxidants in normal physiological functions and human disease, *The International Journal of Biochemistry & Cell Biology*, 39: 44–84
- Volpe, C. M. O. *et al.* (2018) “Cellular death, reactive oxygen species (ROS) and diabetic complications review-Article,” *Cell Death and Disease*, 9(2). doi: 10.1038/s41419-017-0135-z.
- Wang, J. and Wang, H. (2017) “Oxidative stress in pancreatic beta cell regeneration,” *Oxidative Medicine and Cellular Longevity*. Hindawi, 2017. doi: 10.1155/2017/1930261.
- Widowati, W. 2008. *Potensi Antioksidan sebagai Antidiabetes*. 1–11.
- WHO, 2016. Diabetes, WHO media centre fact sheets N°132
- Yunarsa, I. P. P. A., & Adiatmika, I. P. G. (2018). Kadar antioksidan superoksida dismutase (SOD) hati tikus pada aktivitas fisik berat. *E-Jurnal Medika Udayana*, 7, 143–147.

Uji Normalitas

ROS

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K1	.200	6	.200 [*]	.920	6	.505

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K2	.217	6	.200 [*]	.969	6	.885

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K3	.204	14	.119	.860	14	.030

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K4	.129	8	.200 [*]	.961	8	.819

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

MDA

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K1	.167	6	.200 [*]	.932	6	.597

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K2	.191	6	.200 [*]	.912	6	.446

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K3	.352	14	.000	.724	14	.001

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
K4	.225	8	.200 [*]	.884	8	.206

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Karakteristik Dasar Kadar ROS

Descriptive Statistics

	N	Mean	Std. Deviation
K1	6	210.2733	22.83625
K2	6	198.6167	23.73672
K3	14	198.9414	39.86596
K4	8	52.0425	29.24056
Valid N (listwise)	6		

Test Statistics^{a,b}

	ROS
Chi-Square	17.706
df	3
Asymp. Sig.	.001

a. Kruskal Wallis Test

b. Grouping Variable:

Kelompok

Karakteristik Dasar Kadar MDA

Descriptive Statistics

	N	Mean	Std. Deviation
K1	6	.8300	.18612
K2	6	2.9233	1.77774
K3	14	1.4407	.91132
K4	8	1.8937	1.39768
Valid N (listwise)	6		

Test Statistics^{a,b}

	MDA
Chi-Square	9.953
df	3
Asymp. Sig.	.019

a. Kruskal Wallis Test

b. Grouping Variable:

Kelompok

Nilai ROS dalam setiap sub kelompok

Nilai Mean, Standar Deviasi, dan Median K1 H0 dan H17 ROS

		K1 H0 ROS	K1 H17 ROS
N	Valid	2	4
	Missing	32	30
Mean		196.2600	217.2800
Median		196.2600	223.7050
Std. Deviation		15.55635	24.33346

Nilai Mean, Standar Deviasi, dan Median K2 H0, H10, H17 ROS

		K2 H0 ROS	K2 H10 ROS	K2 H17 ROS
N	Valid	2	2	2
	Missing	32	32	32
Mean		216.1800	198.6900	180.9800
Median		216.1800	198.6900	180.9800
Std. Deviation		29.09037	18.85147	19.40301

Nilai Mean, Standar Deviasi, dan Median K3 H0, H10, H17 ROS

		K3 H0 ROS	K3 H10 ROS	K3 H17 ROS
N	Valid	3	3	4
	Missing	1	1	0
Mean		137.7967	213.1533	216.6275
Median		140.8700	221.2100	222.3400
Std. Deviation		37.53449	17.45974	21.35111

Nilai Mean, Standar Deviasi, dan Median K4 H0, H10, H17 ROS

		K4 H0 ROS	K4 H10 ROS	K4 H17 ROS
N	Valid	3	2	3
	Missing	31	32	31
Mean		34.6667	91.0700	43.4000
Median		33.7700	91.0700	53.6000
Std. Deviation		7.34616	21.92031	24.70334

Nilai ROS pada K3

		K3 H0 ROS	K3 H7 ROS	K3 H10 ROS	K3 H17 ROS
N	Valid	3	4	3	4
	Missing	1	0	1	0
Mean		137.7967	216.4550	213.1533	216.6275
Median		140.8700	217.8000	221.2100	222.3400
Std. Deviation		37.53449	22.84579	17.45974	21.35111

Perbandingan Reactive Oxygen Species (ROS) dalam setiap kelompok K1 (H0 vs H17)

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
K1	Equal variances assumed	.383	.569	-1.081	4	.341	-21.02000	19.45356	-75.03174	32.99174
	Equal variances not assumed			-1.282	3.298	.283	-21.02000	16.40211	-70.64893	28.60893

K2 (H0 vs H10)

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
K2 (H0 VS H10)	Equal variances assumed	1.860E+15	.000	.714	2	.550	17.49000	24.51150	-87.97449	122.95449
	Equal variances not assumed			.714	1.714	.560	17.49000	24.51150	-106.77287	141.75287

K2 (H0 vs H17)

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
K2 (H0 VS H17)	Equal variances assumed	2.181E+15	.000	1.424	2	.291	35.20000	24.72576	-71.18637	141.58637
	Equal variances not assumed			1.424	1.743	.307	35.20000	24.72576	-87.74749	158.14749

K2 (H10 vs H17)

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
K2 (H10 VS H17)	Equal variances assumed	2.279E+13	.000	.926	2	.452	17.71000	19.12923	-64.59642	100.01642
	Equal variances not assumed			.926	1.998	.452	17.71000	19.12923	-64.66201	100.08201

K3 (H0 vs H7)

Test Statistics ^a	
	K3 (H0 VS H7)
Mann-Whitney U	.000
Wilcoxon W	6.000
Z	-2.121
Asymp. Sig. (2-tailed)	.034
Exact Sig. [2*(1-tailed Sig.)]	.057 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

K3 (H0 vs H10)

Test Statistics ^a	
	K3 (H0 VS H10)
Mann-Whitney U	.000
Wilcoxon W	6.000
Z	-1.964
Asymp. Sig. (2-tailed)	.050
Exact Sig. [2*(1-tailed Sig.)]	.100 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

K3 (H0 vs H17)

Test Statistics ^a	
	K3 (H0 VS H17)
Mann-Whitney U	.000
Wilcoxon W	6.000
Z	-2.121
Asymp. Sig. (2-tailed)	.034
Exact Sig. [2*(1-tailed Sig.)]	.057 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

K3 (H7 vs H10)

Test Statistics^a

	K3 (H7 VS H10)
Mann-Whitney U	5.000
Wilcoxon W	11.000
Z	-.354
Asymp. Sig. (2-tailed)	.724
Exact Sig. [2*(1-tailed Sig.)]	.857 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

K3 (H7 vs H17)

Test Statistics^a

	K3 (H7 VS H17)
Mann-Whitney U	7.000
Wilcoxon W	17.000
Z	-.289
Asymp. Sig. (2-tailed)	.773
Exact Sig. [2*(1-tailed Sig.)]	.886 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

K3 (H10 vs H17)

Test Statistics^a

	K3 (H10 VS H17)
Mann-Whitney U	6.000
Wilcoxon W	16.000
Z	.000
Asymp. Sig. (2-tailed)	1.000
Exact Sig. [2*(1-tailed Sig.)]	1.000 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

K4 (H0 vs H10)

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
K4 (H0 VS H10)	Equal variances assumed	13.831	.034	-4.412	3	.022	-56.40333	12.78489	-97.09055	-15.71611
	Equal variances not assumed			-3.510	1.152	.150	-56.40333	16.06981	-206.70877	93.90210

K4 (H0 vs H17)

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
K4 (H0 VS H17)	Equal variances assumed	5.843	.073	-.587	4	.589	-8.73333	14.87975	-50.04614	32.57948
	Equal variances not assumed			-.587	2.351	.609	-8.73333	14.87975	-64.41475	46.94809

K4 (H10 vs H17)

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
K4 (H10 VS H17)	Equal variances assumed	.238	.659	2.193	3	.116	47.67000	21.73713	-21.50724	116.84724
	Equal variances not assumed			2.263	2.510	.126	47.67000	21.06344	-27.40121	122.74121

Perbandingan ROS antar kelompok pada H10 dan H17 paska Pemberian Alloxan

Hari	Kelompok	Selisih mean ROS	Selisih median ROS	Nilai p	Nilai p
Hari10	K2 vs K3	14,46	22,52	0,248 ^a	0,107 ^c
	K2 vs K4	107,62	107,62	0,034 ^b	
	K3 vs K4	122,08	130,14	0,083 ^a	
Hari17	K1 vs K2	36,3	42,73	0,145 ^b	0,047 ^c
	K1 vs K3	0,65	1,37	0,773 ^a	
	K1 vs K3	173,88	170,11	0,000 ^b	
	K2 vs K3	35,65	41,36	0,165 ^a	
	K2 vs K4	137,58	127,38	0,007 ^b	
	K3 vs K4	173,23	170,9	0,034 ^a	

^aUji t-Independent, ^aUji Mann Whitney, ^c Uji Kruskal Wallis

Nilai MDA dalam setiap sub kelompok

Nilai Mean, Standar Deviasi, dan Median K1 H0 dan H17 MDA

		K1 H0 MDA	K1 H17 MDA
N	Valid	2	4
	Missing	32	30
Mean		1.0400	.7250
Median		1.0400	.7100
Std. Deviation		.11314	.09678

Nilai Mean, Standar Deviasi, dan Median K2 H0, H10, H17 MDA

		K2 H0 MDA	K2 H10 MDA	K2 H17 MDA
N	Valid	2	2	2
	Missing	32	32	32

Mean	1.0000	3.7450	4.0250
Median	1.0000	3.7450	4.0250
Std. Deviation	.05657	2.12839	.30406

Nilai Mean, Standar Deviasi, dan Median K3 H0, H10, H17 MDA

		K3 H0 MDA	K3 H10 MDA	K3 H17 MDA
N	Valid	3	3	4
	Missing	31	31	30
Mean		1.2967	2.9733	.9250
Median		1.1200	2.8400	.9400
Std. Deviation		.56607	.64049	.09713

Nilai Mean, Standar Deviasi, dan Median K4 H0, H10, H17 MDA

		K4 H0 MDA	K4 H10 MDA	K4 H17 MDA
N	Valid	3	2	3
	Missing	31	32	31
Mean		1.6300	3.9500	.7867
Median		1.6700	3.9500	.9000
Std. Deviation		.37162	.91924	.32517

Nilai MDA pada K3

		K3_H0_MDA	K3_H7_MDA	K3_H10_MDA	K3_H17_MDA
N	Valid	3	4	3	4
	Missing	3	2	3	2
Mean		1.2967	.9150	2.9733	.9250
Median		1.1200	.9350	2.8400	.9400
Std. Deviation		.56607	.09747	.64049	.09713

Perbandingan MDA antar kelompok pada H10 dan H17 paska Pemberian Alloxan

Hari	Kelompok	Selisih mean MDA	Selisih median MDA	Nilai p	Nilai p
Hari10	K2 vs K3	0,77	0,91	1,000 ^a	0,700 ^c
	K2 vs K4	0,21	0,21	0,912 ^b	
	K3 vs K4	0,98	1,11	0,248 ^a	
Hari17	K1 vs K2	3,3	3,32	0,000 ^b	0,070 ^c
	K1 vs K3	0,2	0,23	0,043 ^a	
	K1 vs K3	0,06	0,19	0,727 ^b	
	K1 vs K3	3,1	3,09	0,064 ^a	
	K2 vs K4	3,24	3,13	0,002 ^b	
	K3 vs K4	0,14	0,04	0,858 ^a	

^aUji t-Independent, ^bUji Mann Whitney, ^c Uji Kruskal Wallis

Korelasi ROS dan MDA

K1 ROS – K1 MDA

	K1 ROS	K1 MDA
Pearson Correlation	1	-.393
K1 ROS Sig. (2-tailed)		.441
N	6	6
Pearson Correlation	-.393	1
K1 MDA Sig. (2-tailed)	.441	
N	6	6

K2 ROS – K2 MDA

Correlations			K2 ROS	K2 MDA
	Pearson Correlation		1	-.349
K2 ROS	Sig. (2-tailed)			.497
	N		6	6
	Pearson Correlation		-.349	1
K2 MDA	Sig. (2-tailed)		.497	
	N		6	6

K3 ROS – K3 MDA

Correlations			K3 ROS	K3 MDA
	Correlation Coefficient		1.000	-.046
K3 ROS	Sig. (2-tailed)		.	.876
	N		14	14
Spearman's rho	Correlation Coefficient		-.046	1.000
	Sig. (2-tailed)		.876	.
K3 MDA	Sig. (2-tailed)		.876	.
	N		14	14

K4 ROS – K4 MDA

Correlations			K4 ROS	K4 MDA
	Pearson Correlation		1	.773*
K4 ROS	Sig. (2-tailed)			.024
	N		8	8
	Pearson Correlation		.773*	1
K4 MDA	Sig. (2-tailed)		.024	
	N		8	8

*. Correlation is significant at the 0.05 level (2-tailed).